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1. Introduction 
Since chloramphenicol (C-P) was discovered about 
30 years ago and its broad antibiotic spectrum tested 
in therapeutics, its main metabolic pathways have 
been described. CP is rapidly absorbed in the rat and 
excreted in bile as a glucuronide conjugate [l-4]. 
This compound is readily hydrolysed and converted 
into CP. which is then reduced to aromatrc amines, 
by bacterial action of the gut flora. In man, CP alco- 
hol appears as a metabolite [5]. 
Studies on the mechanism of the toxic side effects 
of CP on bone marrow derived cell have implicated 
other metabolites. An in vitro covalent binding of CP 
to rat liver microsomal proteins was shown after acti- 
vation of CP into an oxamyl chloride which acylates 
proteins [6]. Although the CP oxamic acid has only 
been isolated and characterized in vitro from liver 
microsomes of phenobarbital-treated rats (never with 
normal microsomes), this suggested an hypothetical 
metabolic pathway. It was not confirmed by in vivo 
studies but in vitro [7], a dechlorination of CP by a 
cytosol of rat liver lead to CP aldehyde as a major 
metabolite and metabolic pathways for the formation 
of these metabolites were suggested [7]. 
As CP oxamic acid has never been isolated and 
identified in vivo, an hypothetical pathway of CP 
leading. from CP aldehyde, either to the alcohol or to 
the oxamic acid could not be confirmed. Here, from 
metabolic studies in the rat, we describe the in vivo 
formation of CP oxamic acid. This metabolite has 
been detected, isolated and identified from urine of 
CP-treated rats. Determinations have been performed 
to measure its elimination for 3 days after treatment. 
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2. Materials and methods 
Male OFA rats (-200 g body wt) were held in meta- 
bolic cages. After 15 days acclimation they received a 
single therapeutic dose of CP by stomacchal intu- 
bation. All of them received 8 mg CP dissolved in 
propylene glycol. Besides 3 of them received in the 
same times 20 ,uCi [‘4C]CP (Radio Chemical Center, 
Amersham, 15 mCi/mmol) and 3 others received 8 
mg unlabelled CP plus 80 @i [3 H]CP. [3 H]CP (185 
mCi/mmol) was synthesized by reduction of the 
ketone derivative of CP by NaB3H4 (method derived 
from [6]), the D-Gzreo isomer being then purified by 
high performance liquid chromatography (HPLC). 
Urine samples were collected each day, before treat- 
ment (control) and for 3 days after CP intubation. 
2.1. Extraction 
Urines were extracted twice with SO ml ethyl 
acetate (all solvents were analytical grade). The 
aqueous phase was brought to pH 1.5 with 6 N HCl 
and re-extracted twice with 50 ml ethyl acetate. After 
washing with 2 X 4 ml HzO, the ethyl acetate was eva- 
porated to dryness and the residue dissolved in 2 ml 
methanol. This extract was chromatographied in silica 
gel thin-layer chromatography (TLC):CHCl, -MeOH- 
HaO-CHsCOOH (50:20:3:2) and compared with a 
standard [3H]CP oxamate. Standards CP oxamate and 
[3H]CP oxamate have been synthesized by a method 
adapted from [6] and the purity checked by mass 
spectrometry after gas chromatographic analysis 
(CC-MS) as described below. 
The silica band corresponding to CP oxamate was 
scraped, eluted with water, then brought to pH 1.5 
and extracted with twice 30 ml ethyl acetate. After 
evaporation the dry residue is dissolved in 1 ml 
methanol. 
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2.2. Iderztification 3. Results 
3 H- and l4 C-labelled extracts were transmethylated 
for 2 h at 80°C in the mixture MeOH-& H6-Hz SO+ 
The 3 H and l4 C hydrolysis products were analysed, 
respectively, by radio-HPLC or radio-CC and compared 
to standards of CP base (2-amino-p-nitrophenyl-1,3- 
propanediol) and methylic ester of oxalic acid. Un- 
labelled urine extracts as well as synthetized CP 
oxamic acid were methylated with diazomethane, 
then silylated with BSTFA. The TMS derivatives 
were analysed by CC on a 1 m glass column of Dexil 
300 (3%), (temperature program : 3”C/min from 
220-27O”C, detection by flame ionization) and the 
mass spectra were compared. 
Indirect informations on the structure of the 
urinary metabolite presumed to be CP oxamic acid 
were obtained from the different steps of the analysis 
of the radioactive material. It was extracted at acidic 
pH and has the same RF in the described TLC as Stan- 
dard CP oxamate. Moreover, after the extraction and 
and the first steps of purification, hydrolysis of the 
molecule gave rise to well-defined degradation prod- 
ucts: oxalic acid and CP-base. The radio GC of 14C- 
labelled urine extract, after hydrolysis and trans- 
methylation, shows a peak of same retention time as 
methylic ester of standard oxalic acid chromato- 
graphied in the same conditions (fig.1). In the same 
way, after HPLC and measure of the radioactivity of 
the fractions of the eluate, the hydrolysed 3 H-labelled 
urine extract gives raise to a peak of the same reten- 
tion time as standard unlabelled or tritiated CP-base 
chromatographed in the same conditions and detected 
either by radioactivity or by direct UV absorption at 
280 nm (fig.2). 
2.3. Assays 
The urine extracts from [” H]CP treated animals 
were analysed by radio-HPLC on a 25 cm X 3.1 mm 
id. column packed with 5 pm C1s spherisorb ODS 
(Spectra-Physics). Mobile phase used was water- 
methanol (70 + 30), NaH2P04 0.05 M, at 0.8 ml/ 
min flow rate. Fractions of 250 ~1 were collected, 
fluors mixture added, and the radioactivity measured 
in a liquid scintillation spectrometer. Identification 
and quantitative determinations were performed by 
comparison with a standard [3 H]CP oxamate analysed 




Fig.1. Analysis of the urinary extract from [L4C]CP-treated rats. Radio-GC (3 m glass column of DEGS 15%, 11O’C) of the hydro- 
lysed and transmethylated extract, spiked with standard oxalic acid (as methylic ester). (A) Flame ionization detection; (B) radio- 
activity measurement. 
To confirm these presumptions, direct identifica- 
tion was performed by GC-MS. Fig.3 and 4 show, 
respectively, the analysis of TMS derivatives of stan- 
dard CP oxalic acid and of the urinary extract. Mass 
spectra correspond to the di TMS, methyl derivative; 
in the case of the urinary extract (fig.4), silylation 
was incomplete and another minor peak appears. 
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Fig.2. Analysis of the urinary extract from [ 3 H]CP treated 
rats. Radio-HPLC [25 cm X 2.1 mm column~packed with 
10 ~.lm lichrosorb RP IS-Merck. Mobile phase: H, 0-MeOH 
(65:35), NaH,PO,, 0.1 M pumped at 0.8 ml/min], of the 
hydrolyzed extract spiked with standard CP base. (A) UV de- 
tection at 280 nm; (B) radloactwe counting of the eluate. 
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Both spectra are identical. The mass fragmentation of 
CP oxamic acid is detailed in fig.5, with ions at 
m/e 427, 383,337, 290, 325,218. The ion 427 re- 
presents the loss of 15 amu from the molecular ion, 
which is classically reported for the loss of CH3. In 
the same way, the ions m/e 383 and 337 represent 
the losses of C02-CH3 and NO2 plus CO2 -CH3. 
The ions 290 and 3 18 correspond to the losses of 
CH30 and CH,O-TMS from the CHOTMS-CH- 
(NH-CO-COOMe)-CHzOTMS fragment, plus a rear- 
ranged hydrogen atom. The ion at m/e 225 represents 
the NO* C6H4 CHOTMS fragment plus a rearranged 
225 
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Fig.3. GC-MS analysis of the Me-TMS derivative of the syn- 
thesized standard CP oxamic acid. The di TMS derivative re- 
presents the major peak (91%). 
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Fig.4. CC-MS analysis of the isolated urinary metabolite 
after methylation and sylylation. Mass spectrum corresponds 
to the main peak (I) which is the di TMS derivative and re- 
presents -60% of the total as peak II (-30%) corresponds to 
an incompletely silylated derivative. 
427 .-, 
Fig.5. Mass fragmentation of the CP oxamic acid derivative. 
hydrogen atom, whereas that at m/e 208, described 
[7] is assumed by this author to derive from the m/e 
225 ion by the loss of 17 amu. 
The identity of the urinary metabolite such isolated 
to CP oxamic acid is thus clearly established. 
It must be noticed that no interference has been 
observed with control blank urinary sample either in 
TLC, CC orHPLC analysis. 
In vivo quantitative determinations of CP oxamic 
acid in the urines of [3 H]CP treated rats during 3 days 
after treatment were performed by the radio-HPLC 
described. In these conditions the retention volume 
of the labelled urinary extract is 3.25 ml; it is identical 
to that of standard [” H]CP oxamate and of unlabelled 
standard CP oxamate, detected by UV absorption at 
280 nm. Results are presented in table 1. CP oxan& 
acid appears to represent a major metabolite corre- 
sponding to up to 25% of the radioactivity eliminated 
in urine. 
Table 1 
Urinary elimination of CP oxamic acid after a single oral 
administration of 8 mg CP to rats 
Days after CP oxamic acid (% total 
treatment radioact. eliminated in urine) 
1 25.2 + 0.2 
2 25.7 f 2.5 
3 14.6 +6.1 
Total 
l-3 24.8 + 0.6 
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4. Discussion References 
The identification of CP oxamic acid and its deter- 
mination as a major metabolite appearing in vivo in 
CP-treated rats could confirm the first hypothesis on 
in vitro observations [6], of the formation of a poten- 
tially toxic CP-protein conjugate. The covalent bind- 
ing of CP to protein would occur after activation of 
the CP to CP oxamyl chloride by liver mlcrosomal en- 
zymes. However the presence of such CP oxamate in 
urines of treated animals seems more likely to support 
the metabolic pathway described [7] in rat liver cyto: 
sol which implicates the formation of CP aldehyde by 
a hydrolytic dechlorination. Moreover it appears in 
this work that the CP aldehyde formed that can give 
rise to the CP alcohol metabolite described, can also 
be a precursor to CP oxamyl derivative. In the rat this 
oxidation appears to be a major route of the meta- 
bolic pathway of the CP. The potential pharmaco- 
logical and toxicological importance of this CP oxamyl 
derivative remains to be determined. 
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